Federal Register of Legislation - Australian Government

Primary content

PB 51 of 2012 Determinations/Health as made
This determination amends the National Health (Weighted average disclosed price - third transitional disclosure cycle) Determination 2012 (No. PB 12 of 2012) to add listed brands that were listed on the Pharmaceutical Benefits Scheme (PBS) after the Principal Instrument was made, but prior to the reduction day of 1 August 2012.
Administered by: Health
Registered 25 Jul 2012
Tabling HistoryDate
Tabled HR14-Aug-2012
Tabled Senate14-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 51 of 2012

National Health (Weighted average disclosed price – third transitional disclosure cycle) Amendment Determination 2012

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.

Dated         20 July 2012

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

 

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

 


1              Name of Determination

       (1)     This Determination is the National Health (Weighted average disclosed price – third transitional disclosure cycle) Amendment Determination 2012.

       (2)     This Determination may also be cited as PB 51 of 2012.

2              Commencement

                This Determination commences on the day after it is registered.

 

 

3              Amendments to PB 12 of 2012

Schedule 1 amends the National Health (Weighted average disclosed price – third transitional disclosure cycle) Determination 2012 (PB 12 of 2012).


Schedule 1             Amendments

 

 

[1]      Schedule 1, After

 

17

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

APO-Bisoprolol

44.24

47.57

 

             insert:

 

17A

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Beprol 10

44.24

47.57

 

[2]      Schedule 1, After

 

19

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Bicor

44.24

47.57

 

             insert:

 

19A

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Biso 10

44.24

47.57

 

[3]      Schedule 1, After

 

26

Bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

APO-Bisoprolol

28.32

30.45

 

             insert:

 

26A

Bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

Beprol 2.5

28.32

30.45

 

[4]      Schedule 1, After

 

28

Bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

Bicor

28.32

30.45

 

             insert:

 

28A

Bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

Biso 2.5

28.32

30.45

 

[5]      Schedule 1, After

 

35

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

APO-Bisoprolol

35.39

38.05

 

             insert:

 

35A

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Beprol 5

35.39

38.05

 

[6]      Schedule 1, After

 

37

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Bicor

35.39

38.05

 

             insert:

 

37A

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Biso 5

35.39

38.05

 

[7]      Schedule 1, After

 

47

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/intravesical

Accord Doxorubicin

4.61

4.96

 

             omit:

 

48

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/intravesical

Adriamycin Solution

4.61

4.96

 

[8]      Schedule 1, After

 

51

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 mL single dose vial

Injection/intravesical

Doxorubicin Ebewe

38.97

41.90

 

             omit:

 

52

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial

Injection/intravesical

Adriamycin Solution

8.24

8.86

 

[9]      Schedule 1, After

 

88

Levetiracetam

Tablet 1 g

Oral

Keppra

96.84

104.12

 

             insert:

 

88A

Levetiracetam

Tablet 1 g

Oral

Kerron 1000

96.84

104.12

 

[10]    Schedule 1, After

 

99

Levetiracetam

Tablet 250 mg

Oral

Keppra

34.86

37.48

 

             insert:

 

99A

Levetiracetam

Tablet 250 mg

Oral

Kerron 250

34.86

37.48

 

[11]    Schedule 1, After

 

110

Levetiracetam

Tablet 500 mg

Oral

Keppra

58.12

62.49

 

             insert:

 

110A

Levetiracetam

Tablet 500 mg

Oral

Kerron 500

58.12

62.49

 

[12]    Schedule 1, After

 

149

Meloxicam

Tablet 7.5 mg

Oral

Terry White Chemists Meloxicam 7.5 mg

6.82

7.33

 

             omit:

 

150

Mitozantrone

Injection 10 mg (as hydrochloride) in 5 mL

Injection

Pfizer Australia Pty Ltd

53.34

57.35

 

[13]    Schedule 1, After

 

155

Mitozantrone

Injection 25 mg (as hydrochloride) in 12.5 mL

Injection

Onkotrone

133.29

143.31

 

             omit:

 

156

Mitozantrone

Injection 25 mg (as hydrochloride) in 12.5 mL

Injection

Pfizer Australia Pty Ltd

133.29

143.31

 

[14]    Schedule 1, After

 

160

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Onsetron

1.93

2.08

 

             omit:

 

161

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Pfizer Australia Pty Ltd

1.93

2.08

 

[15]    Schedule 1, After

 

166

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Onsetron

3.06

3.29

 

             omit:

 

167

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Pfizer Australia Pty Ltd

3.06

3.29

 

[16]    Schedule 1, After

 

174

Oxaliplatin

Powder for I.V. infusion 100 mg

Injection

Oxaliplatin Link

79.14

85.09

 

             omit:

 

175

Oxaliplatin

Powder for I.V. infusion 100 mg

Injection

Winthrop Oxaliplatin

79.14

85.09

 

[17]    Schedule 1, After

 

185

Oxaliplatin

Solution concentrate for I.V. infusion 100 mg in 20 mL

Injection

Eloxatin

79.14

85.09

 

             insert:

 

185A

Oxaliplatin

Solution concentrate for I.V. infusion 100 mg in 20 mL

Injection

Oxaliccord

79.14

85.09

 

[18]    Schedule 1, After

 

191

Oxaliplatin

Solution concentrate for I.V. infusion 50 mg in 10 mL

Injection

Eloxatin

40.97

44.05

 

             insert:

 

191A

Oxaliplatin

Solution concentrate for I.V. infusion 50 mg in 10 mL

Injection

Oxaliccord

40.97

44.05

 

[19]    Schedule 2, After

 

10

Fosinopril with Hydrochlorothiazide

Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg

Oral

APO-Fosinopril HCTZ 10/12.5

11.38

 

             omit:

 

11

Fosinopril with Hydrochlorothiazide

Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg

Oral

Fosinopril/HCT Sandoz 10mg/12.5mg

11.38

 

 

 

[20]    Schedule 2, After

 

16

Fosinopril with Hydrochlorothiazide

Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg

Oral

Fosetic 20/12.5

16.72

 

             omit:

 

17

Fosinopril with Hydrochlorothiazide

Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg

Oral

Fosinopril/HCT Sandoz 20mg/12.5mg

16.72

 

 

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.